Abstract
Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 358-376 |
| Number of pages | 19 |
| Journal | Journal of Thoracic Oncology |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2019 |
Fingerprint
Keywords
- Antibody
- Conjugate
- Thoracic malignancies
- Toxophore
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. / Xie, Hao; Adjei, Alex.
In: Journal of Thoracic Oncology, Vol. 14, No. 3, 01.03.2019, p. 358-376.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies
AU - Xie, Hao
AU - Adjei, Alex
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.
AB - Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.
KW - Antibody
KW - Conjugate
KW - Thoracic malignancies
KW - Toxophore
UR - http://www.scopus.com/inward/record.url?scp=85061662820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061662820&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2018.11.034
DO - 10.1016/j.jtho.2018.11.034
M3 - Review article
C2 - 30599202
AN - SCOPUS:85061662820
VL - 14
SP - 358
EP - 376
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 3
ER -